Odyssey Therapeutics Inc(ODTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:46 PM ET (Korea 10/29 05:46)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 59.13% | Shs Outstand | 47.9M | Perf Week | 2.84% |
| Market Cap | 0.94B | Forward P/E | - | EPS next Y | 19.9% | Insider Trans | 17.26% | Shs Float | 19.6M | Perf Month | -12.92% |
| Enterprise Value | 0.65B | PEG | - | EPS next Q | -1.09 | Inst Own | 31.45% | Short Float | 16.71% | Perf Quarter | 6.08% |
| Income | - | P/S | - | EPS this Y | -15.42% | Inst Trans | 70.79% | Short Ratio | 12.7 | Perf Half Y | - |
| Sales | - | P/B | 2.22 | EPS next 5Y | 3.98% | ROA | - | Short Interest | 3.28M | Perf YTD | -2.3% |
| Book/sh | 8.8 | P/C | 3.02 | EPS past 3/5Y | -6.04% - | ROE | - | 52W High | -32.74% ($29.05) | Perf Year | - |
| Cash/sh | 6.46 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 29.4% ($15.10) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 7.16% 7.88% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.52 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.36 | EPS Q/Q | -41.16% | Profit Margin | - | RSI (14) | 49 | Recom | 1.12 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.36 | Sales Q/Q | -100% | SMA20 | 4.14% ($18.76) | Beta | - | Target Price | $35.33 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/09/02 | SMA50 | -11.11% ($21.98) | Rel Volume | 0.81 | Prev Close | $19.5 |
| Employees | - | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | - | SMA200 | -0.89% ($19.72) | Avg Volume(3M) | 0.26M | Price | $19.54 |
| IPO | 2026/5/8 | Option/Short | No/Yes | Trades | 4070 | Volume | 209,227 | Change | 0.21% |
🧬 Odyssey Therapeutics (ODTX) is a clinical-stage biotech company developing oral small-molecule drugs targeting immune and inflammatory diseases. The company pursues differentiated targets such as inflammation-signaling kinase inhibitors for chronic inflammatory diseases including ulcerative colitis, and is channeling the proceeds from its recent Nasdaq listing into advancing its core pipeline into later-stage clinical trials.
Over the past 1 year, roughly in the middle
33% below its 1-year high.
Traded about as much as usual. That is 81% of its average volume.
Growth is moderate
Earnings are expected to grow by -15.4% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 31.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #164 of 594 in the industry
Based on market cap of $939M.
RIGL#163 Rigel Pharmaceuticals $949M PER 3.1 ODTX#164 Odyssey Therapeutics Inc $939M PER - 
MGTX#165 MeiraGTx Holdings plc $936M PER 13.8 
AKTS#166 Aktis Oncology Inc $936M PER - 
JBIO#167 Jade Biosciences Inc $928M PER - 
FAQ
What kind of company is ODTX?
ODTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ODTX?
The market cap of ODTX is approximately $939M, ranking 2,638 within its sector.
What is the 52-week high and low for ODTX?
ODTX has recorded a 52-week high of $29.05 and a low of $15.10.
